SEC Form 4 · accession 0001104659-16-101427
EPIRUS Biopharmaceuticals, Inc. · EPRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Ticktin
Officer — General Counsel
Period of report
Feb 27, 2016
Accepted (ET)
Mar 1, 2016 · 4:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001135906
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 27, 2016 | M | 949 | — | A | 3,949 | D | |
| Common StockF2 | Feb 27, 2016 | M | 2,134 | — | A | 6,083 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | — | Feb 27, 2016 | M | 949 | D | — | — | Common Stock | 949 | 0 | D |
| Restricted Stock UnitsF2 | — | Feb 27, 2016 | M | 2,134 | D | — | — | Common Stock | 2,134 | 6,400 | D |
Explanation of responses
- F1Each Restricted Stock Unit ("RSU") represented a contingent right to receive a share of the Issuer's common stock, vested in full on February 27, 2016, and had no expiration date.
- F2Each RSU represents a contingent right to receive a share of the Issuer's common stock, vests in four (4) substantially equal annual installments beginning on February 27, 2016 provided the Reporting Person remains continuously employed by the Issuer through each vesting date, and has no expiration date.